Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Chief Financial Officer | July 13, 2026 | July 15, 2026 |
| Zura Bio LtdZURA · Entity 5413 | Chief Financial Officer | April 01, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tenaya Therapeutics, Inc.
Report date July 13, 2026 · Filed July 15, 2026
This filing explicitly reported no securities owned.
Zura Bio Ltd
Report date April 01, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.03 · Expires 2036-04-01 | Direct | 340,900 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 340,900 · Balance 340,900 F1: One fourth (1/4th) of the shares subject to the option award shall vest on April 1, 2027, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth (1/4th) of the shares subject to the option award shall vest on April 1, 2027, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Atara Biotherapeutics, Inc.
Report date March 31, 2025 · Filed April 02, 2025
Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $996.25 · Expires 2025-09-03 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-31 · Disposition to issuer · Disposed 1,900 · Balance 0 F4: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $961.75 · Expires 2029-02-05 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-31 · Disposition to issuer · Disposed 460 · Balance 0 F4: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $303.75 · Expires 2030-02-28 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-03-31 · Disposition to issuer · Disposed 496 · Balance 0 F4: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $303.75 · Expires 2030-02-28 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-31 · Disposition to issuer · Disposed 154 · Balance 0 F4: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. F1: 1/11th of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vested in equal monthly installments over the following ten (10) months, subject to the reporting person's continuous service. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $427.63 · Expires 2031-02-28 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-31 · Disposition to issuer · Disposed 381 · Balance 0 F4: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $427.63 · Expires 2031-02-28 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-03-31 · Disposition to issuer · Disposed 350 · Balance 0 F4: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. F2: 1/23rd of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vested in equal monthly installments over the following twenty-two (22) months, subject to the reporting person's continuous service. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $255.25 · Expires 2032-02-29 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-03-31 · Disposition to issuer · Disposed 262 · Balance 0 F4: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $255.25 · Expires 2032-02-29 | Direct | 160 |
Reported balance
After 2025-03-31 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-03-31 · Disposition to issuer · Disposed 543 · Balance 160 F4: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. F3: 1/35th of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vest in equal monthly installments over the following thirty-four (34) months, subject to the reporting person's continuous service. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.75 · Expires 2033-02-28 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-03-31 · Disposition to issuer · Disposed 331 · Balance 0 F4: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.75 · Expires 2033-02-28 | Direct | 2,656 |
Reported balance
After 2025-03-31 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-03-31 · Disposition to issuer · Disposed 8,961 · Balance 2,656 F4: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. F3: 1/35th of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vest in equal monthly installments over the following thirty-four (34) months, subject to the reporting person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/11th of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vested in equal monthly installments over the following ten (10) months, subject to the reporting person's continuous service.
F2: 1/23rd of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vested in equal monthly installments over the following twenty-two (22) months, subject to the reporting person's continuous service.
F3: 1/35th of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vest in equal monthly installments over the following thirty-four (34) months, subject to the reporting person's continuous service.
F4: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2026 Filed Jul 15, 2026 01:00 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 1,650,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001193125-26-303681 · ownership.xml · derivative · entry 1 Hyllengren Eric J · CIK 0001966926 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,650,000 Underlying: Common Stock · 1,650,000 shares Expires 2036-07-12 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2024 Inducement Equity Incentive Plan. Option will vest as to 1/4th of the total number of shares subject to the option on the one-year anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 22:00 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantEmployee Share Option (Right to Buy) · Derivative | 340,900 | $0.00 Strike: $6.03 | $0.00 |
DisclosureSEC source: 0001966926-26-000002 · form4-04022026_060416.xml · derivative · entry 1 Hyllengren Eric J · CIK 0001966926 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,900 Underlying: Class A Ordinary Shares · 340,900 shares Expires 2036-04-01 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on April 1, 2027, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:20 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantEmployee Share Option (Right to Buy) · Derivative | 672,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001415889-25-019965 · form4-07172025_090704.xml · derivative · entry 1 Hyllengren Eric J · CIK 0001966926 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 672,000 Underlying: Class A Ordinary Shares · 672,000 shares Expires 2035-07-15 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on July 7, 2026, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 23:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 8,961 | $0.00 Strike: $97.75 | $0.00 |
DisclosureSEC source: 0000905148-25-001058 · form4.xml · derivative · entry 10 Hyllengren Eric J · CIK 0001966926 · Former EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,656 Underlying: Common Stock · 8,961 shares Expires 2033-02-28 F4 · price: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. F3 · derivative.exercise_date: 1/35th of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vest in equal monthly installments over the following thirty-four (34) months, subject to the reporting person's continuous service. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 23:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 331 | $0.00 Strike: $97.75 | $0.00 |
DisclosureSEC source: 0000905148-25-001058 · form4.xml · derivative · entry 9 Hyllengren Eric J · CIK 0001966926 · Former EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 331 shares Expires 2033-02-28 F4 · price: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 23:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 543 | $0.00 Strike: $255.25 | $0.00 |
DisclosureSEC source: 0000905148-25-001058 · form4.xml · derivative · entry 8 Hyllengren Eric J · CIK 0001966926 · Former EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160 Underlying: Common Stock · 543 shares Expires 2032-02-29 F4 · price: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. F3 · derivative.exercise_date: 1/35th of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vest in equal monthly installments over the following thirty-four (34) months, subject to the reporting person's continuous service. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 23:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 262 | $0.00 Strike: $255.25 | $0.00 |
DisclosureSEC source: 0000905148-25-001058 · form4.xml · derivative · entry 7 Hyllengren Eric J · CIK 0001966926 · Former EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 262 shares Expires 2032-02-29 F4 · price: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 23:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 350 | $0.00 Strike: $427.63 | $0.00 |
DisclosureSEC source: 0000905148-25-001058 · form4.xml · derivative · entry 6 Hyllengren Eric J · CIK 0001966926 · Former EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 350 shares Expires 2031-02-28 F4 · price: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. F2 · derivative.exercise_date: 1/23rd of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vested in equal monthly installments over the following twenty-two (22) months, subject to the reporting person's continuous service. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 23:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 381 | $0.00 Strike: $427.63 | $0.00 |
DisclosureSEC source: 0000905148-25-001058 · form4.xml · derivative · entry 5 Hyllengren Eric J · CIK 0001966926 · Former EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 381 shares Expires 2031-02-28 F4 · price: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 23:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 154 | $0.00 Strike: $303.75 | $0.00 |
DisclosureSEC source: 0000905148-25-001058 · form4.xml · derivative · entry 4 Hyllengren Eric J · CIK 0001966926 · Former EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 154 shares Expires 2030-02-28 F4 · price: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. F1 · derivative.exercise_date: 1/11th of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vested in equal monthly installments over the following ten (10) months, subject to the reporting person's continuous service. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 23:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 496 | $0.00 Strike: $303.75 | $0.00 |
DisclosureSEC source: 0000905148-25-001058 · form4.xml · derivative · entry 3 Hyllengren Eric J · CIK 0001966926 · Former EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 496 shares Expires 2030-02-28 F4 · price: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 23:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 460 | $0.00 Strike: $961.75 | $0.00 |
DisclosureSEC source: 0000905148-25-001058 · form4.xml · derivative · entry 2 Hyllengren Eric J · CIK 0001966926 · Former EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 460 shares Expires 2029-02-05 F4 · price: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 23:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 1,900 | $0.00 Strike: $996.25 | $0.00 |
DisclosureSEC source: 0000905148-25-001058 · form4.xml · derivative · entry 1 Hyllengren Eric J · CIK 0001966926 · Former EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,900 shares Expires 2025-09-03 F4 · price: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,211 | $7.00 | $8,473.37 |
DisclosureSEC source: 0000905148-25-000864 · form4.xml · nonDerivative · entry 1 Hyllengren Eric J · CIK 0001966926 · EVP, CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,231 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 3, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:52 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 34,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000245 · form4.xml · nonDerivative · entry 1 Hyllengren Eric J · CIK 0001966926 · EVP, CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,442 F1 · shares: These restricted stock units ("RSUs") vest as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following January 27, 2025, and as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the next seven Quarterly Vesting Dates, such that all of the shares subject to the RSUs shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous service. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:04 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,364 | $11.20 | $15,274.07 |
DisclosureSEC source: 0000905148-24-003242 · form4.xml · nonDerivative · entry 1 Hyllengren Eric J · CIK 0001966926 · EVP, CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,392 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 18, 2024 and November 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 29 | $6.63 | $192.30 |
DisclosureSEC source: 0000905148-24-002303 · form4.xml · nonDerivative · entry 2 Hyllengren Eric J · CIK 0001966926 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,756 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,041 | $6.63 | $6,900.79 |
DisclosureSEC source: 0000905148-24-002303 · form4.xml · nonDerivative · entry 1 Hyllengren Eric J · CIK 0001966926 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,785 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. F3 · balance_after: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024. Read SEC document |
| May 16, 2024 Filed May 21, 2024 00:33 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 28,648 | $0.62 | $17,675.82 |
DisclosureSEC source: 0000905148-24-001558 · form4.xml · nonDerivative · entry 1 Hyllengren Eric J · CIK 0001966926 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645,671 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2024 and May 17, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,217 | $0.72 | $3,756.24 |
DisclosureSEC source: 0000905148-24-000908 · form4.xml · nonDerivative · entry 2 Hyllengren Eric J · CIK 0001966926 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 674,319 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 4, 2024 and March 5, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,462 | $0.72 | $1,054.10 |
DisclosureSEC source: 0000905148-24-000908 · form4.xml · nonDerivative · entry 1 Hyllengren Eric J · CIK 0001966926 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 679,536 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 4, 2024 and March 5, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 21:40 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 475,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000112 · form4.xml · nonDerivative · entry 1 Hyllengren Eric J · CIK 0001966926 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 680,998 F1 · shares: These restricted stock units vest as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following January 8, 2024, and as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the next seven Quarterly Vesting Dates, such that all of the shares shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous service. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 22:29 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 11,958 | $0.39 | $4,651.66 |
DisclosureSEC source: 0000905148-23-001509 · form4.xml · nonDerivative · entry 1 Hyllengren Eric J · CIK 0001966926 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,998 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 22:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,778 | $1.65 | $2,940.81 |
DisclosureSEC source: 0001140361-23-040564 · form4.xml · nonDerivative · entry 2 Hyllengren Eric J · CIK 0001966926 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,956 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 22:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,408 | $1.65 | $10,586.02 |
DisclosureSEC source: 0001140361-23-040564 · form4.xml · nonDerivative · entry 1 Hyllengren Eric J · CIK 0001966926 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,734 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| May 16, 2023 Filed May 19, 2023 00:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,719 | $2.04 | $3,503.32 |
DisclosureSEC source: 0001140361-23-025558 · form4.xml · nonDerivative · entry 2 Hyllengren Eric J · CIK 0001966926 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,142 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2023 and May 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| May 16, 2023 Filed May 19, 2023 00:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,199 | $2.04 | $12,627.36 |
DisclosureSEC source: 0001140361-23-025558 · form4.xml · nonDerivative · entry 1 Hyllengren Eric J · CIK 0001966926 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,861 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2023 and May 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.